Cambridge Cognition Holdings (COG)

Sector:

Health Care

Index:

FTSE AIM All-Share

25.50p
   
  • Change Today:
    -4.50p
  • 52 Week High: 82.50
  • 52 Week Low: 23.25
  • Currency: UK Pounds
  • Shares Issued: 27.64m
  • Volume: 122,893
  • Market Cap: £7.05m
  • RiskGrade: 273

Cambridge Cognition gains client with improved electronic assessment platform

By Josh White

Date: Monday 25 Nov 2019

LONDON (ShareCast) - (Sharecast News) - Brain health solutions developer Cambridge Cognition Holdings announced the launch of an improved electronic clinical outcomes assessment ('eCOA') platform on Monday, claiming it had already attracted a new client from one of the world's top 10 pharmaceutical companies.
The AIM-traded firm explained that clinicians and patients complete clinical outcome assessments (COAs), such as questionnaires and scales, during clinical trials in order to monitor the effects of treatment.

It said that, with the ubiquity of electronic devices, those necessary assessments were increasingly being delivered on smartphones, tablets and desktops - so much so that the eCOA market was estimated to reach $2bn (£1.55bn) by 2025.

Cambridge Cognition said that, after investing proceeds from the fundraise earlier in the year, it had expanded its eCOA offering to include complex forms, alerting, interview recording and playback.

Following the launch of the enhanced functionality, it announced a new clinical trial contract worth more than $0.23m.

The company said its eCOA solution could be "rapidly configured" for each new clinical trial, which meant that deployment of new clinical outcome instruments would take a matter of days, rather than weeks or months, once the licences were secured.

It said the new contract had tight study deadlines, with multiple outcome assessments for more than 100 patients across five time-points.

In using the company's automated assessment system, the administrative burden for sites was said to be reduced, while consistency in data collection and quality was still ensured.

Crucially, Cambridge Cognition said having a single platform to deliver both electronic questionnaires and scales, alongside its 'CANTAB' cognitive assessments, provided a "seamless user experience" for the patient.

"Increasingly, pharmaceutical and biotech companies are recognising the operational benefits of delivering questionnaires and scales electronically in their clinical trials," said chief executive officer Matthew Stork.

"Our new eCOA offering enables us to capitalise on this shift and to provide an extremely fast turn-around from contract agreement to study deployment.

"We are pleased to see that the investment in development made this year has already helped us to build a new relationship with another prestigious partner."

At 0801 GMT, shares in Cambridge Cognition were up 6.46% at 28.74p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

COG Market Data

Currency UK Pounds
Share Price 25.50p
Change Today -4.50p
% Change -15.00 %
52 Week High 82.50
52 Week Low 23.25
Volume 122,893
Shares Issued 27.64m
Market Cap £7.05m
RiskGrade 273

COG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
11.78% below the market average11.78% below the market average11.78% below the market average11.78% below the market average11.78% below the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average
Price Trend
94.27% below the market average94.27% below the market average94.27% below the market average94.27% below the market average94.27% below the market average
95.12% below the sector average95.12% below the sector average95.12% below the sector average95.12% below the sector average95.12% below the sector average
Income Not Available
Growth
37.53% below the market average37.53% below the market average37.53% below the market average37.53% below the market average37.53% below the market average
37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average

COG Dividends

No dividends found

Trades for 19-Feb-2020

Time Volume / Share Price
15:33 75,000 @ 23.75p
16:28 1,000 @ 25.40p
16:03 5,000 @ 25.50p
15:52 3,000 @ 25.00p
15:49 4,046 @ 25.70p

COG Key Personnel

Chair Michael Geoffrey Lewis
CFO Nick Walters
CEO Matthew Stork

Top of Page